SCHEMBL8778585

SCHEMBL8778585

N#Cc1ccc2c(Br)c(C(=O)C(F)(F)F)ccc2n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMKK2 Q96RR4 2/20 0.33
PLA2G2D Q9UNK4 1/20 0.33
NQO1 P15559 1/20 0.33
MALT1 Q9UDY8 1/20 0.33
ABL1 P00519 1/20 0.32
MAP2K2 P36507 1/20 0.32
CSNK1A1 P48729 1/20 0.32
CLK2 P49760 1/20 0.32
GSK3A P49840 1/20 0.32
GSK3B P49841 1/20 0.32
CDK5 Q00535 1/20 0.32
ACVR1 Q04771 1/20 0.32
CLK4 Q9HAZ1 1/20 0.32
DYRK1B Q9Y463 1/20 0.32
CTSB P07858 2/20 0.32
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
PDE4D Q08499 1/20 0.31
CES1 P23141 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5020169 0.84 MALT1 (0.34) CAMKK2PLA2G2DNQO1MALT1ABL1
SCHEMBL16914971 0.78 L3MBTL1 (0.44) CAMKK2NQO1PDE4APDE4BPDE4C
SCHEMBL8778506 0.74 PLA2G2D (0.32) PLA2G2D
SCHEMBL8745771 0.73 ESR1 (0.51) NQO1CTSB
SCHEMBL8745764 0.70 NQO1 (0.42) NQO1CTSB
SCHEMBL14747557 0.69 CTSS (0.38) NQO1
SCHEMBL14747555 0.67 NQO1 (0.37) NQO1
SCHEMBL16915197 0.65 NQO1 (0.41) CAMKK2NQO1PDE4APDE4BPDE4C
SCHEMBL31324958 0.65 SOS2 (0.41) CAMKK2CTSBMAPK1
SCHEMBL838145 0.65 ALDH1A1 (0.41) CAMKK2CTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120129886-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129886-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO CAMKK2 820/4885PLA2G2D 1687/4885NQO1 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.